Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kurma Partners has established itself as a leading European venture capital group focused on healthcare innovation. It co-founds and invests in biotech and healthtech startups spun out from top academic research institutions across Europe. Its funds have supported successful exits such as Amolyt Pharma (acquired by AstraZeneca), Emergence Therapeutics (acquired by Eli Lilly), and Corlieve Therapeutics (acquired by BioMarin). The current Biofund IV aims to invest in up to 20 new biotech/healthcare companies developing innovative therapeutics addressing high unmet medical needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kurma Partners.